An international specialty pharma company

Meda is a leading international specialty pharma company. The company is represented in all of Europe and the US by its own marketing subsidiaries.

Meda's products are sold in 120 countries worldwide. During 2008, the company's net sales surpassed SEK 10 billion.

Meda's shares are traded on Nasdaq OMX Nordic Exchange in Stockholm.

LATEST NEWS

	Meda in-licenses exclusive rights to Ceplene 2010-01-11 - 28,0 KB
	FDA accepts NDA filing for Retigabine 2009-12-30 - 14,1 KB
	Meda expands Axorid collaboration 2009-12-30 - 14,3 KB
	Meda strengthens the financial headroom 2009-12-07 - 13,5 KB
	Interim report January - September 2009 2009-11-03 - 85,2 KB
	Retigabine filings completed in the US and Europe 2009-11-02 - 13,8 KB
	Nomination committee appointed 2009-10-26 - 16,3 KB
	Onsolis filed in Canada 2009-10-02 - 19,6 KB
	Expanded rights for azelastine and fluticasone combination 2009-09-07 - 16,9 KB
	FDA Approval of the first once-daily nasal antihistamine 2009-09-02 - 22,3 KB
	More news ť

Priority therapy areas are
respiratory, cardiology, pain and inflammation, dermatology and CNS.

Meda's shares are traded on Nasdaq OMX Nordic Exchange in Stockholm under Large Cap.